Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 8/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336251 | 0.82 | VCAM1 (0.48) | TRPV4IDO1SLC22A12SRCMAOA | |
| SCHEMBL769392 | 0.78 | MAOB (0.42) | TRPV4MAOAMAOB | |
| SCHEMBL21201454 | 0.77 | IDO1 (0.37) | TRPV4IDO1 | |
| SCHEMBL3431834 | 0.77 | IDO1 (0.37) | TRPV4IDO1SRC | |
| SCHEMBL101711 | 0.76 | TRPV4 (0.61) | TRPV4ARCYP11B2IDO1MAOA | |
| SCHEMBL21687452 | 0.76 | TRPV4 (0.35) | TRPV4ARMAOAMAOB | |
| SCHEMBL27659042 | 0.74 | TRPV4 (0.59) | TRPV4ARCYP11B2IDO1SLC22A12 | |
| SCHEMBL2947436 | 0.74 | TRPV4 (0.59) | TRPV4ARCYP11B2IDO1SLC22A12 | |
| SCHEMBL25179564 | 0.73 | TRPV4 (0.38) | TRPV4SRCMAOAMAOB | |
| SCHEMBL518867 | 0.73 | TRPV4 (0.57) | TRPV4ARCYP11B2IDO1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008782-A1 | HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2026-01-08 | — | — | US | disclosed |
| WO-2025202185-A1 | PROCESS FOR THE FUNCTIONALIZATION OF AN AROMATIC OR HETEROAROMATIC AMINO COMPOUND | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-10-02 | — | — | WO | disclosed |
| EP-4624456-A1 | PROCESS FOR THE DEAMINATIVE HALOGENATION OF AN AROMATIC OR HETEROAROMATIC AMINO COMPOUND | Studiengesellschaft Kohle gGmbH (DE) | 2025-10-01 | — | — | EP | disclosed |
| CN-119998288-A | Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024073658-A1 | HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11225500-B2 | Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, L-proline and water | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-01-18 | — | — | US | disclosed |
| US-20210139520-A1 | SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| EP-3275867-B1 | PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1339695-B1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| CN-1487924-A | Farnesyl transferase inhibitors | ���Ͽع�����˾ | 2004-04-07 | — | — | CN | disclosed |
| EP-1339695-A1 | FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002074747-A1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225500-B2 | Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, L-proline and water | COL1A1, DCXR, PLOD1 | TRPV4 3767/4885AR 3720/4885CYP11B2 2222/4885 |
| US-20210139520-A1 | SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER | COL1A1, DCXR, PLOD1 | TRPV4 3741/4885AR 3725/4885CYP11B2 2219/4885 |
| US-20260008782-A1 | HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | SGMS1, MAG, SGMS2 | TRPV4 4449/4885AR 4870/4885CYP11B2 723/4885 |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | FNTB, FNTA, ACAT2 | TRPV4 4730/4885AR 4691/4885CYP11B2 1040/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | TRPV4 4841/4885AR 4696/4885CYP11B2 260/4885 |
| US-20030087940-A1 | Farnesyltransferase inhibitors | FNTB, FNTA, FDPS | TRPV4 4839/4885AR 4652/4885CYP11B2 207/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | TRPV4 4373/4885AR 4525/4885CYP11B2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.